ArticleCardiovascular research2023
Transthyretin cardiac amyloidosis.
Article in Cardiovascular research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 86 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
86 citing papers in PubMed, 2 syntheses or guidelines pooled it, 154 citations in OpenAlex.
- Sodium-glucose cotransporter 2 inhibitors and outcomes in transthyretin amyloid cardiomyopathy: Systematic review and meta-analysis.European journal of clinical investigation · 2025Pooled it
- Associations of Patients with Pericardial Effusion Secondary to Light-Chain or Transthyretin Amyloidosis- A Systematic Review.Current cardiology reviews · 2024Pooled it
- Screening Criteria for Amyloidosis Biopsy Testing during Carpal Tunnel Release in Community Hospitals: Evaluation and Application.Journal of wrist surgery · 2026Article
- Evaluation of the diagnostic value of dual-time-point, multi-parameter 99mTc-PYP imaging in diagnosing Transthyretin Cardiac Amyloidosis.The international journal of cardiovascular imaging · 2026Article
- Transthyretin Cardiac Amyloidosis in Women: Underdiagnosis, Sex-Specific Phenotypic Expression and Therapeutic Response.Journal of clinical medicine · 2026Review
- A simple nomogram to help guide the diagnosis of cardiac amyloidosis in patients with heart failure with preserved ejection fraction.Quantitative imaging in medicine and surgery · 2026Article
- UniqueAnnals of laboratory medicine · 2026Article
- Classification of cardiomyopathies: bringing order to complexity.European heart journal supplements : journal of the European Society of Cardiology · 2026Article
- Development and Internal validation of a simple echocardiography score for diagnosis of cardiac amyloidosis.Journal of thoracic disease · 2026Article
- Cardiorenal Biomarkers and their Implications in Prognosis and Treatment Response of Transthyretin Cardiac Amyloidosis.Current heart failure reports · 2026Review
- Prediagnostic Electrocardiographic Abnormalities in Transthyretin Amyloid Cardiomyopathy: A Longitudinal Observational Study.Journal of clinical medicine · 2026Article
- Standardizing the Definition of Early Diagnosis in Wild-Type Transthyretin Amyloidosis.JACC. Advances · 2026Article
- Amyloidosis in Carpal Tunnel Syndrome and 1-Year Cardiovascular and Renal Outcomes: A Propensity Score-Matched Cohort Study.Journal of the American Heart Association · 2026Article
- Novel Cut-Off Values of Precordial Voltage Indexes for Light Chain Amyloidosis Cardiomyopathy in a Chinese Population.Journal of cardiovascular development and disease · 2026Article
- Transthyretin amyloid cardiomyopathy: from cause to novel treatments.European heart journal · 2026Review
- Reduced heart rate variability is associated with disease severity in AL amyloidosis: a retrospective cohort study.Frontiers in medicine · 2026Article
- Article
- Expanding the scope of SGLT inhibitors in underrepresented cardiac populations: from pathophysiology to clinical evidence.Frontiers in cardiovascular medicine · 2026Review
- The Vagal Link: Autonomic Nervous System Dysfunction in Cardiac Amyloidosis.Journal of clinical medicine · 2025Review
- Navigating the emerging landscape of asymptomatic ATTR-CM: challenges, opportunities and the path ahead.Future cardiology · 2025Review
26 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
Abstract
Transthyretin cardiac amyloidosis (ATTR-CA) is an increasingly recognized cause of heart failure (HF) and mortality worldwide. Advances in non-invasive diagnosis, coupled with the development of effective treatments, have shifted ATTR-CA from a rare and untreatable disease to a relatively prevalent condition that clinicians should consider on a daily basis. Amyloid fibril formation results from age-related failure of homoeostatic mechanisms in wild-type ATTR (ATTRwt) amyloidosis (non-hereditary form) or destabilizing mutations in variant ATTR (ATTRv) amyloidosis (hereditary form). Longitudinal large-scale studies in the United States suggest an incidence of cardiac amyloidosis in the contemporary era of 17 per 100 000, which has increased from a previous estimate of 0.5 per 100 000, which was almost certainly due to misdiagnosis and underestimated. The presence and degree of cardiac involvement is the leading cause of mortality both in ATTRwt and ATTRv amyloidosis, and can be identified in up to 15% of patients hospitalized for HF with preserved ejection fraction. Associated features, such as carpal tunnel syndrome, can preceed by several years the development of symptomatic HF and may serve as early disease markers. Echocardiography and cardiac magnetic resonance raise suspicion of disease and might offer markers of treatment response at a myocardial level, such as extracellular volume quantification. Radionuclide scintigraphy with 'bone' tracers coupled with biochemical tests may differentiate ATTR from light chain amyloidosis. Therapies able to slow or halt ATTR-CA progression and increase survival are now available. In this evolving scenario, early disease recognition is paramount to derive the greatest benefit from treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.